Document is current
Any future updates will be listed below
-
Authors
Gomes, Bruna http://orcid.org/0000-0002-3349-927X
Singh, Aditya http://orcid.org/0000-0003-0827-7429
O’Sullivan, Jack W. http://orcid.org/0000-0003-3629-2546
Schnurr, Theresia M.
Goddard, Pagé C.
Loong, Shaun
Amar, David http://orcid.org/0000-0002-9719-0837
Hughes, J. Weston
Kostur, Mykhailo
Haddad, Francois
Salerno, Michael
Foo, Roger http://orcid.org/0000-0002-8079-4618
Montgomery, Stephen B. http://orcid.org/0000-0002-5200-3903
Parikh, Victoria N. http://orcid.org/0000-0002-5138-5559
Meder, Benjamin http://orcid.org/0000-0003-0741-2633
Ashley, Euan A. http://orcid.org/0000-0001-9418-9577
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (GO 3196/3-1, 707766 - 809341)
Novo Nordisk Foundation
- License Information
-
More Information
Article History
Received: 7 October 2022
Accepted: 23 October 2023
First Online: 11 December 2023
Competing interests
: B.M. is part of the Scientific Advisory Board of Fleischhacker GmbH. E.A. is the founder of Personalis, DeepCell, Svexa, Overtone and Parameter Health; advisor to Pacific Biosciences, SequenceBio, Nuevocor and Apple and a nonexecutive director of AstraZeneca. J.S. is a consultant for Google AI. S.B.M. is an advisor to BioMarin, Myome and Tenaya Therapeutics. V.P. is SAB for BioMarin and Lexeo Therapeutics; a consultant for Viz.ai and Nuevocor and has sponsored research from Biomarin, Inc. and Saliogen Therapeutics. M.S. receives research support from Siemens Healthineers and GE Healthcare and is a consultant to Medtronic, G3 and Imagion Biosciences. All other authors have no conflicts of interest to declare.
